Veracyte, Inc.

New findings from the randomized Phase III STAMPEDE trial took the stage at #ESMO26 today. Here’s a recap from a session where Sarah Howlett, M.B.B.S., University College London (UCL), presented results from a combination analysis of STAMPEDE and real-world datasets. The talk highlighted how the Decipher® Prostate Genomic Classifier can predict benefit from adding abiraterone to androgen deprivation therapy (ADT) in men with clinically very high-risk #ProstateCancer, whose disease had not spread to lymph nodes. | Primary Takeaways | 🔹 Transcriptomic signatures showed consistent associations with metastatic outcomes across both STAMPEDE and real-world datasets. 🔹 Higher Decipher scores identified patients with higher rates of distant metastasis and those most likely to benefit from the addition of abiraterone. 🔹 Lower Decipher scores correlated with lower rates of distant metastasis, potentially providing means for guiding safe treatment de-escalation. | Some Thank You’s | 💙 We’re grateful to Dr. Howlett for sharing this research with the oncology community and for her continued dedication to improving care for the millions of men living with prostate cancer worldwide. 💙 Thank you to everyone who joined the session and to the investigators, site teams, and participants whose contributions made this research possible. | Additional Resources | 🔗 Event information - https://lnkd.in/gP8bdHcM 🔗 Decipher Prostate Genomic Classifier - https://lnkd.in/g-739FJD #PrecisionOncology #ClinicalResearch #RealWorldData #DecipherProstate #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - https://lnkd.in/gkcXNFPc

Today, we announced the acquisition of Convergent Genomics, adding Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to our product portfolio. UroAmp has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance, and is supported by a robust and growing body of evidence. | Why This Matters | 🔹 Expanded capabilities: This acquisition strengthens our ability to deliver powerful complementary genomic insights from urine, tissue, and blood, helping guide bladder cancer care across the patient journey. 🔹 First Product: Our initial test will be intended to help determine whether patients who have had Bacillus Calmette-Guerin (BCG) induction therapy are likely to benefit from maintenance treatment. We expect to commercialize this test in late 2028, subject to reimbursement timelines. 🔹 Forward direction: We plan to expand our use of the UroAmp platform to additional indications, including intravesical maintenance therapy monitoring and surveillance following treatment with curative intent. | Resources | 📄 Read the full press release - https://lnkd.in/gUisCGzg 🔗 Learn more about Veracyte - https://www.veracyte.com Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit: https://lnkd.in/gkcXNFPc #Veracyte #VCYT #CancerDiagnostics #PrecisionMedicine #Acquisition #InvestorRelations

Today, we announced strong second-quarter 2026 financial results, reflecting continued momentum across our #CancerDiagnostics portfolio: 🔹 $150.3 million in total revenue, up 15% year over year 🔹 $145.7 million in testing revenue, up 19% year over year 🔹 $44.0 million in adjusted EBITDA, representing 29.2% of revenue Q2 was also a milestone quarter, marked by the U.S. launches of the Prosigna® Breast Risk of Recurrence Test and the TrueMRD™ Monitoring Test for patients with muscle-invasive bladder cancer. Together, these offerings expand our ability to serve more patients across the cancer care continuum. | Resources | 🔹 View #Q2Earnings Presentation - https://lnkd.in/gQvY6Vh2 🔹 Explore our technology and pipeline - https://lnkd.in/gdG-ePmy 🔹 Learn about some of our active clinical studies - https://lnkd.in/gxHh7Mve #Veracyte #InvestorRelations #VCYT #PrecisionMedicine Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - https://lnkd.in/gpHMFcjH

More personalized cancer care starts with clearer answers. In this Investor’s Business Daily feature by Allison Gatlin, our CEO Marc Stapley highlights how Veracyte’s genomic tests, such as the Prosigna® Breast and Decipher® Prostate tests, are helping guide treatment decisions to support a new era of #PrecisionOncology. Read the full story: https://lnkd.in/gyP_zkMN | Clinical Resources | #ProsignaBreastRORTest - https://lnkd.in/gdNAYpJj #DecipherProstate - https://lnkd.in/g-739FJD #CancerDiagnostics #BreastCancer #ProstateCancer #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - https://lnkd.in/gkcXNFPc

More than 2/3 of patients with positive nodes may avoid chemotherapy when guided by the Prosigna® Breast ROR test.¹ What could that mean for your treatment decisions? Join OPTIMA lead investigator Prof. Rob Stein and Veracyte's Dr. Kelly Marcom for a deeper look at the phase III results behind Prosigna test-directed chemotherapy. 📅 June 24 · 12:00 PM EDT / 9:00 AM PDT ➡️ Reserve your spot below. ¹Stein RC, et al. ASCO. 2026.

We are thrilled to announce that the Prosigna® Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer, is officially available to order in the U.S.! Thank you to Nasdaq for featuring us on their Times Square tower in honor of this important milestone in breast cancer care. | Impact | In the U.S., more than 225,000 new HR+/HER2- breast cancer cases are diagnosed each year. It is critically important to accurately determine a patient's risk of recurrence because the effects of treatment escalation or de-escalation can have a lasting impact on a patient's life. On the heels of the landmark #OPTIMA trial readout at #ASCO26, the #ProsignaTest now offers clinicians and the patients not only a deeper understanding of individual risk of recurrence (ROR) for their hormone receptor positive (HR+) breast cancer, but for many, if chemotherapy can benefit them or if they may safely avoid it. Developed from the #PAM50 genomic classifier, the Prosigna test is the only test that combines intrinsic subtypes and proliferation score with clinical pathological factors to provide a comprehensive 10-year probability of distant recurrence. Additionally, the Prosigna Breast ROR test is the only test proven to be predictive for chemotherapy benefit for premenopausal and post-menopausal patients with high-clinical risk HR+ breast cancer with up to 9 positive lymph nodes. | Access and Availability | The Prosigna test is available to order through Veracyte's network nationwide via the Veracyte Ordering Portal. The test is currently covered by many commercial payers, and patients may qualify for financial assistance or a tailored payment plan supported by the Veracyte Access Program for eligible uninsured and underinsured patients. 🔗 How to order the Prosigna test - https://lnkd.in/gXVbviRt | Resources | 🔹 Prosigna test clinical resources - https://lnkd.in/gdNAYpJj 🔹 View Prosigna test sample reports - https://lnkd.in/gdbKmmuM #ProsignaBreastRORTest #BreastCancer #PrecisionMedicine #CancerDiagnostics Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit: https://lnkd.in/gkcXNFPc